Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy

Atherosclerosis

Volumn 203, Issue 2, 2009, Pages 371-376

  Chasman, Daniel I ^a   Shiffman, Dov ^b   Zee, Robert Y L ^a   Louie, Judy Z ^b   Luke, May M ^b   Rowland, Charles M ^b   Catanese, Joseph J ^b   Buring, Julie E ^a   Devlin, James J ^b   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CELERA   (United States)

Author keywords

Aspirin; Cardiovascular disease; Genetics; Lipoproteins; Lp(a)

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A; LIPOPROTEIN A; PLACEBO;

ADULT; AGE DISTRIBUTION; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; GENOTYPE; HEART INFARCTION; HETEROZYGOTE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WOMEN'S HEALTH;

ALLELES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOLIPOPROTEINS A; ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 62649151842     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.07.019     Document Type: Article

References (30)

1. Marcovina S.M., and Koschinsky M.L. Lipoprotein(a): structure, measurement, and clinical significance. In: Rifai N., Warnick G.R., and Dominiczak M.H. (Eds). Handbook of lipoprotein testing (2000), AACC Press, Washington, DC 345-385
2. Berglund L., and Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 24 (2004) 2219-2226
3. Hobbs H.H., and White A.L. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 10 (1999) 225-236
4. Danesh J., Collins R., and Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102 (2000) 1082-1085
5. Ridker P.M., Buring J.E., Rifai N., and Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women. JAMA 297 (2007) 611-619
6. Suk Danik J., Rifai N., Buring J.E., and Ridker P.M. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 296 (2006) 1363-1370
7. Paultre F., Pearson T.A., Weil H.F., et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and White men. Arterioscler Thromb Vasc Biol 20 (2000) 2619-2624
8. Baldassarre D., Tremoli E., Franceschini G., Michelagnoli S., and Sirtori C.R. Plasma lipoprotein(a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients. Stroke 27 (1996) 1044-1049
9. Kronenberg F., Kronenberg M.F., Kiechl S., et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck Study. Circulation 100 (1999) 1154-1160
10. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353 (2005) 46-57
11. Boffa M.B., Marcovina S.M., and Koschinsky M.L. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 37 (2004) 333-343
12. Hancock M.A., Boffa M.B., Marcovina S.M., Nesheim M.E., and Koschinsky M.L. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 278 (2003) 23260-23269
13. Caplice N.M., Panetta C., Peterson T.E., et al. Lipoprotein(a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 98 (2001) 2980-2987
14. Strater R., Becker S., von Eckardstein A., et al. Prospective assessment of risk factors for recurrent stroke during childhood-a 5-year follow-up study. Lancet 360 (2002) 1540-1545
15. Angles-Cano E., Hervio L., Rouy D., et al. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator. Chem Phys Lip 67-8 (1994) 369-380
16. Marcovina S.M., and Koschinsky M.L. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 14 (2003) 361-366
17. Gabel B.R., and Koschinsky M.L. Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry 34 (1995) 15777-15784
18. Luke M.M., Kane J.P., Liu D.M., et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 27 (2007) 2030-2036
19. Shiffman D., O'Meara E.S., Bare L.A., et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 28 (2008) 173-179
20. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
21. Lee I.M., Cook N.R., Gaziano J.M., et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 294 (2005) 56-65
22. Marcovina S.M., Albers J.J., Scanu A.M., et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 46 (2000) 1956-1967
23. Ridker P.M., Rifai N., Cook N.R., Bradwin G., and Buring J.E. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294 (2005) 326-333
24. Kronenberg F., Lingenhel A., Lhotta K., et al. Lipoprotein(a)- and low density lipoprotein-derived cholesterol in nephrotic syndrome: impact on lipid-lowering therapy?. Kidney Int 66 (2004) 348-354
25. Hancock M.A., Spencer C.A., and Koschinsky M.L. Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance. Biochemistry 43 (2004) 12237-12248
26. Akaike M., Azuma H., Kagawa A., et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 48 (2002) 1454-1459
27. Kagawa A., Azuma H., Akaike M., Kanagawa Y., and Matsumoto T. Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem 274 (1999) 34111-34115
28. Gavish D., Azrolan N., and Breslow J.L. Plasma Ip(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a) gene. J Clin Invest 84 (1989) 2021-2027
29. Ogorelkova M., Kraft H.G., Ehnholm C., and Utermann G. Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. Hum Mol Genet 10 (2001) 815-824
30. Utermann G., Menzel H.J., Kraft H.G., et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80 (1987) 458-465